Clinical Trial Update: A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone [Phase 2]

View source ↗

Summary

Phase 2 study of Onapristone ER alone or with Anastrozole in progesterone-responsive gynecologic cancers has completed. Results were posted in July 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrioid Endometrial Cancer
• Granulosa Cell Ovarian Cancer
• Low-grade Serous Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Onapristone ER (onapristone)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-07-28